CareDx, Inc. (CDNA) Stock Price & Analysis
CareDx, Inc. (CDNA) closed at USD 69.16 on Thursday, October 22, 2026, down 2.23% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 70.74; the Oct 22, 2026 session ranged USD 66.84–71.51 on volume of 917,863 shares. Market capitalization is $3.58B, with a 52-week range of USD 14.03–72.71 (NGM). Source: Nexqual, retrieved October 23, 2026 at 09:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CDNA.md
Key facts (CDNA)
- Last four reported quarters (through Jun 30, 2026): revenue $458M, net income $111M (24.2% margin) (SEC filings).
- Valuation: P/E 32.2x (avg 23.1x at the last 1 fiscal year-ends).
- 1 of 80 tracked superinvestors hold CDNA (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.29 on a 1–5 scale) (7 analysts), mean target USD 64.17 (range 46–80).
- Total return with dividends: 1Y +370.5% vs S&P 500 +14.9%; 5Y -4.0% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 0.26, revenue estimate $122M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CDNA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $296M | $322M | $280M | $334M | $380M | $458M |
| Operating income | -$29.7M | -$77.2M | -$203M | $40.8M | -$30.8M | $108M |
| Net income | -$30.7M | -$76.6M | -$190M | $52.5M | -$21.4M | $111M |
| EPS (diluted) | -$0.59 | -$1.44 | -$3.54 | $0.93 | -$0.40 | — |
| Operating margin | -10.0% | -24.0% | -72.5% | 12.2% | -8.1% | 23.6% |
| Net margin | -10.3% | -23.8% | -67.9% | 15.7% | -5.6% | 24.2% |
| Revenue growth | +54.2% | +8.6% | -12.9% | +19.1% | +13.8% | — |
| Cash + short-term investments | $348M | $293M | $235M | $261M | $177M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CDNA)
P/E 32.2x · P/S 7.8x · P/B 8.4x · Earnings yield 3.10%
P/E at fiscal year-ends: Dec 2024 23.1x.
Superinvestors (SEC 13F-HR, Q2 2026) (CDNA)
1 of 80 tracked investors hold CDNA. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.03% | $17.1M | Added +4.0% |
Analysts (CDNA)
Consensus Buy (mean 2.29 on a 1–5 scale), 7 analysts; mean target USD 64.17 (low 46, high 80).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Canaccord Genuity | Target raised | Buy | $65 → $80 |
| 2026-09-24 | BTIG | Target raised | Buy | $60 → $74 |
| 2026-09-02 | Canaccord Genuity | Initiated | Buy | $65 |
| 2026-08-06 | BTIG | Target raised | Buy | $45 → $60 |
| 2026-07-31 | HC Wainwright & Co. | Reiterated | Neutral | $46 |
| 2026-07-16 | BTIG | Target raised | Buy | $28 → $45 |
Total return (dividends reinvested) (CDNA)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +370.5% | -4.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +373.0% | -0.8% |
| Volatility (annualized) | 68.7% | 78.3% |
| Max drawdown | -23.6% (Jan 2026→Apr 2026) | -93.1% (Oct 2021→Oct 2023) |
CDNA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.26 | $0.19 | +35.6% | $122.0M | 6 |
| Next quarter (ends Dec 2026) | $0.23 | $0.17 | +36.3% | $123.5M | 6 |
| Current fiscal year (ends Dec 2026) | $1.20 | $0.93 | +28.3% | $495.1M | 6 |
| Next fiscal year (ends Dec 2027) | $1.29 | $1.13 | +13.8% | $526.0M | 6 |
CDNA options: expected move
Options price a move of about ±19.2% (±$13.30) by Nov 20, 2026, which includes earnings on Oct 29, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 85.0% | ±19.2% |
| Dec 18, 2026 | 56 | 70.8% | ±22.3% |
| Feb 19, 2027 | 119 | 63.7% | ±28.9% |
| Mar 19, 2027 | 147 | 64.3% | ±32.4% |
| May 21, 2027 | 210 | 62.8% | ±37.6% |
| Nov 19, 2027 | 392 | 58.6% | ±47.3% |
30-day implied volatility 85.9% vs 57.6% realized over the last 30 trading days. Put/call ratio (volume) 0.56. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:24 UTC)
| Price | USD 69.16 |
|---|---|
| Change | ▼ 2.23% (down) |
| Previous Close | USD 70.74 |
| Open | USD 69.65 |
| Day Range | USD 66.84 – 71.51 |
| 52-Week Range | USD 14.03 – 72.71 |
| Volume | 917,863 shares |
| Market Cap | $3.58B |
| Exchange | NGM |
Technical Analysis (CDNA)
Nexqual's technical model rates CDNA "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:24 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 64.37 (neutral) |
| vs SMA50 | Above (USD 56.71) |
| MACD | 3.49 (positive) |
Analyst Ratings (CDNA)
Wall Street analysts rate CDNA "Buy" based on 7 analysts, with a mean price target of USD 64.17 (range USD 46–80), per Nexqual as of October 23, 2026 at 09:24 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 64.17 |
| High Target | USD 80 |
| Low Target | USD 46 |
| Buy / Hold / Sell | 5 / 2 / 0 |
Earnings (CDNA)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 0.26 |
| Revenue Estimate | $121.95M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.37 vs est 0.23 ▲ beat |
| 2026-03-31 | USD 0.34 vs est 0.13 ▲ beat |
| 2025-12-31 | USD 0.12 vs est 0.23 ▼ miss |
| 2025-09-30 | USD 0.28 vs est 0.14 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financials & Fundamentals (CDNA)
| Total Revenue | $458.09M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +52.20% |
| Gross Margin | +70.58% |
| Operating Margin | +0.19% |
| Profit Margin | +24.23% |
| ROE | +29.49% |
| Debt / Equity | 0.05 |
| Current Ratio | 4.58 |
| Total Cash | $373.64M |
| Total Debt | $19.25M |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financial Health Score (CDNA)
Nexqual rates CareDx, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:24 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 71%, operating 0% (last 12 months) |
| Balance Sheet | Strong — $374M cash vs $19M debt, net cash position |
| Cash Flow | Solid — Operating cash flow $42M (FY ended Dec 2025, 10-K) |
| Efficiency | Strong — ROE 29%, ROA -0.3% |
Ownership (CDNA)
| Insider Ownership | +3.10% |
|---|---|
| Institutional Ownership | +103.85% |
| Shares Outstanding | 51.73M |
| Float | 49.46M |
| Short % of Float | +12.97% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Leadership (CDNA)
CareDx, Inc. is led by John Walter Hanna, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:24 UTC.
| President, CEO & Director | John Walter Hanna |
|---|---|
| CFO & COO | Keith S. Kennedy C.F.A. |
| Chief Technology Officer | Kashif Rathore |
| Chief Scientific Officer | Robert N. Woodward |
| Vice President of Corporate Communications | Natasha Moshirian Wagner |
Major Backers & Investors (CDNA)
Notable institutional backers of CareDx, Inc. include Deerfield Management Company, L.P, ARK Invest, Boston Partners, according to Nexqual as of October 23, 2026 at 09:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deerfield Management Company, L.P | 3.86% |
| ARK Invest | 3.78% |
| Boston Partners | 3.75% |
| BAMCO Inc. | 3.74% |
| Gagnon Securities, LLC | 3.42% |
| Chevy Chase Trust Holdings, LLC | 2.78% |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 2.66% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.31% |
| State Street | 4.77% |
| Vanguard Group | 4.25% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VCYT | Veracyte, Inc. | USD 46.04 | ▼ 0.39% |
| ADPT | Adaptive Biotechnologies Corpor | USD 24.41 | ▼ 3.63% |
| BLLN | BillionToOne, Inc. | USD 105.68 | ▲ 0.96% |
| SHC | Sotera Health Company | USD 18.13 | ▲ 2.03% |
| RDNT | RadNet, Inc. | USD 70.26 | ▲ 2.7% |
| GRAL | GRAIL, Inc. | USD 127.06 | ▼ 4.18% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt